346 related articles for article (PubMed ID: 29690784)
1. Bevacizumab biosimilars: scientific justification for extrapolation of indications.
Melosky B; Reardon DA; Nixon AB; Subramanian J; Bair AH; Jacobs I
Future Oncol; 2018 Oct; 14(24):2507-2520. PubMed ID: 29690784
[TBL] [Abstract][Full Text] [Related]
2. SB8, an approved bevacizumab biosimilar based on totality of evidence: scientific justification of extrapolation.
Peeters M; Lipp HP; Park M; Yoon YC; Arnold D
Future Oncol; 2023 Feb; 19(6):427-450. PubMed ID: 36883661
[TBL] [Abstract][Full Text] [Related]
3. Scientific rationale for extrapolation of biosimilar data across cancer indications: case study of CT-P10.
Ogura M; Coiffier B; Kwon HC; Yoon SW
Future Oncol; 2017 May; 13(15s):45-53. PubMed ID: 28482699
[TBL] [Abstract][Full Text] [Related]
4. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar.
Thomas M; Thatcher N; Goldschmidt J; Ohe Y; McBride HJ; Hanes V
Immunotherapy; 2019 Oct; 11(15):1337-1351. PubMed ID: 31556762
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer.
Taïeb J; Aranda E; Raouf S; Dunn H; Arnold D
Clin Colorectal Cancer; 2021 Mar; 20(1):42-51.e3. PubMed ID: 33243618
[TBL] [Abstract][Full Text] [Related]
6. Biosimilars are coming: ready or not.
Zalcberg J
Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
[TBL] [Abstract][Full Text] [Related]
7. [Opportunities and challenges of extrapolation for biosimilars].
Weise M; Wolff-Holz E
Z Gastroenterol; 2016 Nov; 54(11):1211-1216. PubMed ID: 27711947
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars: Here and Now.
Lemery SJ; Esteva FJ; Weise M
Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
[TBL] [Abstract][Full Text] [Related]
9. Application of the FDA Biosimilar Extrapolation Framework to Make Off-Label Determinations.
Li E; Lobaina E
J Manag Care Spec Pharm; 2017 Dec; 23(12):1227-1232. PubMed ID: 29172978
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars.
Rosen LS; Jacobs IA; Burkes RL
Target Oncol; 2017 Oct; 12(5):599-610. PubMed ID: 28801849
[TBL] [Abstract][Full Text] [Related]
11. Pharmacist perspectives and considerations for implementation of therapeutic oncology biosimilars in practice.
Cuellar S; McBride A; Medina P
Am J Health Syst Pharm; 2019 Oct; 76(21):1725-1738. PubMed ID: 31612935
[TBL] [Abstract][Full Text] [Related]
12. FDA's Approval of the First Biosimilar to Bevacizumab.
Casak SJ; Lemery SJ; Chung J; Fuchs C; Schrieber SJ; Chow ECY; Yuan W; Rodriguez L; Gwise T; Rowzee A; Lim S; Keegan P; McKee AE; Pazdur R
Clin Cancer Res; 2018 Sep; 24(18):4365-4370. PubMed ID: 29743182
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars and the extrapolation of indications for inflammatory conditions.
Tesser JR; Furst DE; Jacobs I
Biologics; 2017; 11():5-11. PubMed ID: 28255229
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
Ben-Horin S; Vande Casteele N; Schreiber S; Lakatos PL
Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1685-1696. PubMed ID: 27215364
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
Hung A; Vu Q; Mostovoy L
J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
[TBL] [Abstract][Full Text] [Related]
16. The rise of oncology biosimilars: from process to promise.
Verrill M; Declerck P; Loibl S; Lee J; Cortes J
Future Oncol; 2019 Oct; 15(28):3255-3265. PubMed ID: 31441323
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars: Extrapolation for oncology.
Curigliano G; O'Connor DP; Rosenberg JA; Jacobs I
Crit Rev Oncol Hematol; 2016 Aug; 104():131-7. PubMed ID: 27354233
[TBL] [Abstract][Full Text] [Related]
18. Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.
Schiestl M; Zabransky M; Sörgel F
Drug Des Devel Ther; 2017; 11():1509-1515. PubMed ID: 28553082
[TBL] [Abstract][Full Text] [Related]
19. Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices.
Ebbers HC; Chamberlain P
BioDrugs; 2016 Feb; 30(1):1-8. PubMed ID: 26758077
[TBL] [Abstract][Full Text] [Related]
20. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
Agarwal AB; McBride A
Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
